NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, News, & Analysis

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) announced its quarterly earnings results on Tuesday, August, 7th. The biotechnology company reported $0.97 earnings per share for the quarter, missing analysts' consensus estimates of $0.98 by $0.01. The biotechnology company had revenue of $57.26 million for the quarter, compared to analyst estimates of $56.59 million. Enanta Pharmaceuticals had a return on equity of 25.84% and a net margin of 37.63%. View Enanta Pharmaceuticals' Earnings History.

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 19th 2018. View Earnings Estimates for Enanta Pharmaceuticals.

6 analysts have issued 1 year price objectives for Enanta Pharmaceuticals' stock. Their predictions range from $80.00 to $133.00. On average, they expect Enanta Pharmaceuticals' share price to reach $108.25 in the next year. This suggests a possible upside of 10.8% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Enanta Pharmaceuticals.

Some companies that are related to Enanta Pharmaceuticals include Amneal Pharmaceuticals (AMRX), SAGE Therapeutics (SAGE), Ionis Pharmaceuticals (IONS), Catalent (CTLT), Alkermes (ALKS), GALAPAGOS NV/S (GLPG), Dr.Reddy's Laboratories (RDY), Ligand Pharmaceuticals (LGND), United Therapeutics (UTHR), FibroGen (FGEN), Loxo Oncology (LOXO), Ultragenyx Pharmaceutical (RARE), Agios Pharmaceuticals (AGIO), GW Pharmaceuticals PLC- (GWPH) and Taro Pharmaceutical Industries (TARO).

Press coverage about ENTA stock has trended somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Enanta Pharmaceuticals earned a coverage optimism score of 0.18 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 46.57 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Enanta Pharmaceuticals.

Enanta Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.63%), Renaissance Technologies LLC (4.56%), First Manhattan Co. (2.95%), Acadian Asset Management LLC (1.98%), Bank of New York Mellon Corp (1.28%) and Bank of New York Mellon Corp (1.27%). Company insiders that own Enanta Pharmaceuticals stock include Jay R Luly, Nathalie Adda, Paul J Mellett and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

ENTA stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, First Manhattan Co., Eqis Capital Management Inc., State of Wisconsin Investment Board, United Services Automobile Association, Alps Advisors Inc., Alps Advisors Inc. and California Public Employees Retirement System. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Jay R Luly, Nathalie Adda and Paul J Mellett. View Insider Buying and Selling for Enanta Pharmaceuticals.

ENTA stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, First Trust Advisors LP, BlackRock Inc., Federated Investors Inc. PA, Russell Investments Group Ltd., WINTON GROUP Ltd, Renaissance Technologies LLC and American Century Companies Inc.. View Insider Buying and Selling for Enanta Pharmaceuticals.

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ENTA stock can currently be purchased for approximately $97.68.

Enanta Pharmaceuticals has a market capitalization of $1.76 billion and generates $102.81 million in revenue each year. The biotechnology company earns $17.71 million in net income (profit) each year or $0.91 on an earnings per share basis. Enanta Pharmaceuticals employs 89 workers across the globe.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]